Sling Therapeutics
PrivateLast Round
Series C
Sep 16, 2026
Est. Valuation
$140M
Total Funding Raised
$158M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Sling Therapeutics operates in Healthcare & Life Sciences and is based in Ann Arbor, Michigan. Its latest recorded funding round was a Series C round in September 2026.
Sling Therapeutics is a biopharmaceutical company focused on developing oral small molecule linsitinib to provide innovative treatment options for patients in the ophthalmology, endocrinology, and rare disease sectors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sling Therapeutics Comparables
Compare Sling Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Khartis Therapeutics | 87% | |
| Lirum Therapeutics | 83% | |
| Ethyreal Bio | 81% |
For institutional investors. Book with your work email.
Sling Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 16, 2026 | ||||
| Series A | Jun 13, 2022 |
For institutional investors. Book with your work email.
Sling Therapeutics Investors
Notable investors and investment history
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 16, 2026
$123M round led by Forbion
- Jul 26, 2026
Monthly visitors increased 47% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 10, 2026
Sling Therapeutics, Inc. presents efficacy, safety and durability findings from its Phase 2b/3 LIDS trial of oral linsitinib in adults with moderate to severe active thyroid eye disease at the American Society of Ophthalmic Plastic and Reconstructive Surgery 57th Annual Fall Scientific Symposium on Oct 9th '26.
- receives_financingSep 16, 2026
Sling Therapeutics, Inc. closed a $123M Series C financing led by Forbion, with participation from TPG Life Sciences Innovations and Sectoral Asset Management, to support its Phase III confirmatory trial for linsitinib, in Michigan on Sep 16th '26.
- hiresSep 16, 2026
Sling Therapeutics, Inc. appoints François Beaubien of Sectoral Asset Management to its board of directors in conjunction with its $123 million Series C financing in Sep '26.
- hiresSep 16, 2026
Sling Therapeutics, Inc. appoints Regina Salvat of Forbion to its board of directors alongside François Beaubien of Sectoral Asset Management as part of a financing.
For institutional investors. Book with your work email.
Sling Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Sling Therapeutics's valuation, stock price, and market status.
Is Sling Therapeutics a public or private company?
Sling Therapeutics is a private company.
What is the current stock price of Sling Therapeutics?
Sling Therapeutics is a private company, so its shares have no public market price. Caplight tracks Sling Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sling Therapeutics worth (valuation)?
Sling Therapeutics's valuation is estimated at $140.0M based on funding round data.
Can I buy Sling Therapeutics stock?
Sling Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sling Therapeutics's last funding round?
Sling Therapeutics's most recent funding round was Series C on September 16, 2026.
Who are the main investors in Sling Therapeutics?
Key investors in Sling Therapeutics include Forbion, TPG.
Will Sling Therapeutics IPO soon?
No public IPO plans have been announced for Sling Therapeutics.
How can I track Sling Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Sling Therapeutics's shares on secondary markets.